Atara Biotherapeutics (ATRA) Reiterated at Buy by Stifel, Fatal SAE is Disappointing, but Ultimately ATA188 Should Dominate the Sentiment
Tweet Send to a Friend
Stifel analyst Benjamin Burnett reiterated a Buy rating on Atara Biotherapeutics (NASDAQ: ATRA), following announcement of a fatal incident in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
